Thrombosis最新文献

{"title":"The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty.","authors":"Robert D Russell,&nbsp;William R Hotchkiss,&nbsp;Justin R Knight,&nbsp;Michael H Huo","doi":"10.1155/2013/762310","DOIUrl":"https://doi.org/10.1155/2013/762310","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) is a common complication after total hip and total knee arthroplasty. Currently used methods of VTE prophylaxis after these procedures have important limitations, including parenteral administration, and unpredictable plasma levels requiring frequent monitoring and dose adjustment leading to decreased patient compliance with recommended guidelines. New oral anticoagulants have been demonstrated in clinical trials to be equally efficacious to enoxaparin and allow for fixed dosing without the need for monitoring. Rivaroxaban is one of the new oral anticoagulants and is a direct factor Xa inhibitor that has demonstrated superior efficacy to that of enoxaparin. However, the data also suggest that rivaroxaban has an increased risk of bleeding compared to enoxaparin. This paper reviews the available data on the efficacy and safety of rivaroxaban for VTE prophylaxis after total hip and total knee arthroplasty.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":" ","pages":"762310"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/762310","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40228968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The avantgarde carbostent in patients scheduled for undelayable noncardiac surgery.","authors":"Carlo Briguori,&nbsp;Gabriella Visconti,&nbsp;Francesca De Micco,&nbsp;Amelia Focaccio","doi":"10.1155/2012/372371","DOIUrl":"https://doi.org/10.1155/2012/372371","url":null,"abstract":"<p><p>Background. Treatment of patients who need coronary revascularization before undelayable non-cardiac surgery is challenging. Methods. We assessed the safety and efficacy of percutaneous coronary interventions (PCI) using the Avantgarde( TM) Carbostent (CID, Italy) in patients undergoing PCI before undelayable non-cardiac surgery. The Multiplate analyzer point-of-care was used to assess residual platelet reactivity. One major cardiac events (MACE, defined as death, myocardial infarction, and stent thrombosis and major bleeding) were assessed. Results. 42 consecutive patients were analyzed. Total stent length ≥25 mm was observed in 16 (37%) patients. Multivessel stenting was performed in 11 (31.5%) patients. Clopidogrel was interrupted 5 days before surgery in 35 patients, whereas it was stopped the day of the surgery in 7 patients. Surgery was performed after 27 ± 9 (7-42) days from PCI. MACE occurred in one patient (2.4%; 95% confidence interval: 0.01-13%), who had fatal acute myocardial infarction 3 days after abdominal aortic aneurysm surgery and 12 days after stent implantation. No case of major bleeding in the postoperative phase was observed. Conclusions. The present pilot study suggests that, although at least 10-14 days of dual antiplatelet therapy remain mandatory, the Avantgarde( TM) stent seems to have a role in patients requiring undelayable surgery.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"372371"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/372371","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30529057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathological perspective of drug-eluting stent thrombosis.","authors":"Katsumi Inoue","doi":"10.1155/2012/219389","DOIUrl":"https://doi.org/10.1155/2012/219389","url":null,"abstract":"<p><p>Although very late stent thrombosis (VLST) after drug-eluting stent (DES) implantation remains a major concern, the precise mechanisms have not been clarified. An association between late acquired incomplete stent apposition (ISA) and VLST of DES has been suggested by several intravascular ultrasound studies demonstrating very high prevalence of ISA in the setting of VLST. To clarify the pathological mechanisms of VLST, we investigated vascular responses of coronary arteries of VLST cases after DES implantation.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"219389"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/219389","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30665944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms.","authors":"Bianca Rocca,&nbsp;Giovanna Petrucci","doi":"10.1155/2012/376721","DOIUrl":"https://doi.org/10.1155/2012/376721","url":null,"abstract":"<p><p>The main pharmacological aspects of pharmacodynamics (PD) and pharmacokinetics (PK) of aspirin as antiplatelet agent were unravelled between the late sixties and the eighties, and low-dose aspirin given once daily has been shown to be a mainstay in the current treatment and prevention of cardiovascular disorders. Nevertheless, several PD and PK aspects of aspirin in selected clinical conditions have recently emerged and deserve future clinical attention. In 1994, the term \"aspirin resistance\" was used for the first time, but, until now, no consensus exists on definition, standardized assay, underlying mechanisms, clinical impact, and possible efficacy of alternative therapeutic interventions. At variance with an undefined aspirin-resistant status, in the last 5 years, the concept of variability in response to aspirin due to specific pathophysiological mechanisms and based on PK and/or PD of the drug has emerged. This growing evidence highlights the existence and possible clinical relevance of an interindividual variability of pharmacological aspirin response and calls for new, large studies to test new low-dose aspirin-based regimens which may ameliorate platelet acetylation, reduce variability in drug responsiveness, and improve clinical efficacy on selected populations.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"376721"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/376721","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30421559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Role of Compression Stockings in Preventing Post thrombotic Syndrome: A Review of the Literature.","authors":"Abir O Kanaan,&nbsp;Jayne E Lepage,&nbsp;Shabdis Djazayeri,&nbsp;Jennifer L Donovan","doi":"10.1155/2012/694851","DOIUrl":"https://doi.org/10.1155/2012/694851","url":null,"abstract":"<p><p>Background. Postthrombotic syndrome (PTS) is a burdensome and costly complication of deep vein thrombosis (DVT). Up to 50% of patients with DVT will develop the disease within two years following the diagnosis of acute DVT. Various risk factors for developing PTS have been identified and different modalities have been used to prevent its development. Compression stockings have been studied for the prevention of PTS in patients diagnosed with proximal DVT. Methods. MEDLINE and EMBASE databases were searched to identify relevant original articles. Results. Several trials including two metaanalyses have examined the role of compression stockings for the prevention of PTS. Although most trials showed significant reduction in the development of PTS with the use of compression stockings, limitations in study design prevent the generalizability of the data. Two studies supported an individualized tailored duration especially in patients at low risk for developing the syndrome. A randomized double-blind placebo-controlled trial involving 800 patients is currently ongoing and may confirm the results of older studies. Conclusions. Clinical trials support the use of compression stockings in patients diagnosed with proximal DVT for the prevention of PTS.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"694851"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/694851","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30443957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging \"real-world\" questions.","authors":"Jorge Ferreira, Daniel Ferreira, Miguel Viana-Baptista, Paulo Bettencourt, Rui Cernadas, Francisco Crespo","doi":"10.1155/2012/867121","DOIUrl":"10.1155/2012/867121","url":null,"abstract":"<p><p>Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is the joint effort of a panel of experts from different specialties and provides information on the use of dabigatran, in anticipation of the challenges that will come with increased usage.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"867121"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30654027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of RANKL/OPG Serum Concentration Ratio as a New Biomarker for Coronary Artery Calcification: A Pilot Study.","authors":"Amir Hooshang Mohammadpour,&nbsp;Jamal Shamsara,&nbsp;Saeed Nazemi,&nbsp;Samira Ghadirzadeh,&nbsp;Shabnam Shahsavand,&nbsp;Mohammad Ramezani","doi":"10.1155/2012/306263","DOIUrl":"https://doi.org/10.1155/2012/306263","url":null,"abstract":"<p><p>Objective. There is a strong need for biomarkers to identify patients at risk for future cardiovascular events related with progressive atherosclerotic disease. Osteoprotegerin (OPG) protects the skeleton from excessive bone resorption by binding to receptor activator of nuclear factor-κB ligand (RANKL) and preventing it from binding to its receptor, receptor activator of nuclear factor-κB. However, conflicting results have been obtained about association of serum level of OPG or RANKL with coronary artery disease (CAD). Based on their role in inflammation and matrix degradation and the fact that atherosclerotic plaque formation is an inflammatory process, we hypothesized that RANKL : OPG ratio could be a better biomarker for CAD. Methods. In this cross-sectional study, the correlation between RANKL : OPG ratio serum concentration and coronary artery calcification (CAC) in 50 patients with ischemic coronary disease has been investigated. We used ELISA method for measuring RANKL and OPG serum concentrations. Results. There was a significant correlation between RANKL : OPG serum concentration ratio and CAC in our study population (P = 0.01). Conclusion. Our results suggested that RANKL : OPG ratio concentration has a potential of being used as a marker for coronary artery disease.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"306263"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30610561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stent thrombosis: incidence, predictors and new technologies.","authors":"Gill Louise Buchanan,&nbsp;Sandeep Basavarajaiah,&nbsp;Alaide Chieffo","doi":"10.1155/2012/956962","DOIUrl":"https://doi.org/10.1155/2012/956962","url":null,"abstract":"<p><p>Some concerns have been raised regarding the risk of late and very late stent thrombosis (ST) following drug-eluting stent implantation. Despite remaining an uncommon complication of percutaneous coronary intervention, when ST occurs, it can be catastrophic to the individual, commonly presenting as acute ST elevation myocardial infarction or sudden cardiac death. The incidence and predictors of ST have been reported in the literature and the role of dual antiplatelet therapies in the avoidance of such a complication remains vital. Ongoing studies are assessing the role of these therapies including platelet reactivity testing, genetic testing and optimum duration of therapy. In addition, newer polymer-free and bioabsorbable stents are under investigation in the quest to potentially minimise the risk of ST.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"956962"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/956962","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30610564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials.","authors":"Ashraf Alazzoni,&nbsp;Ayman Al-Saleh,&nbsp;Sanjit S Jolly","doi":"10.1155/2012/126369","DOIUrl":"https://doi.org/10.1155/2012/126369","url":null,"abstract":"<p><p>Background. Individual randomized trials have suggested that everolimus-eluting stents may have improved clinical outcomes compared to paclitaxel-eluting stents, but individual trials are underpowered to examine outcomes such as mortality and very late stent thrombosis. Methods. Medline, Cochrane, and conference proceedings were searched for randomized trials comparing everolimus versus paclitaxel-eluting stents for percutaneous coronary intervention. Results. 6792 patients were included from 4 randomized controlled trials. Stent thrombosis was reduced with everolimus stents versus paclitaxel stents (0.7% versus 2.3%; OR: 0.32; CI: 0.20-0.51; P < 0.00001). The reductions in stent thrombosis were observed in (i) early stent thrombosis (within 30 days) (0.2% versus 0.9%; OR: 0.24; P = 0.0005), (ii) late (day 31-365) (0.2% versus 0.6%; OR: 0.32; P = 0.01), and (iii) very late stent thrombosis (>365 days) (0.2% versus 0.8%; OR: 0.34; P = 0.009). The rates of cardiovascular mortality were 1.2% in everolimus group and 1.6% in paclitaxel group (OR: 0.85; P = 0.43). Patients receiving everolimus-eluting stents had significantly lower myocardial infarction events and target vessel revascularization as compared to paclitaxel-eluting stents. Interpretation. Everolimus compared to paclitaxel-eluting stents reduced the incidence of early, late, and very late stent thrombosis as well as target vessel revascularization.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"126369"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/126369","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30659676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombosis and aspirin: clinical aspect, aspirin in cardiology, aspirin in neurology, and pharmacology of aspirin.","authors":"Christian Doutremepuich","doi":"10.1155/2012/626289","DOIUrl":"https://doi.org/10.1155/2012/626289","url":null,"abstract":"Acetyl salicylic acid or aspirin is one of the most famous drugs in the world. Aspirin has been increasingly used for prevention of cardiovascular events and is, particularly in recent decades, the most used nonsteroidal anti-inflammatory drug. \u0000 \u0000Thus, it was necessary to have several contributions to precise the interest and the side effects of aspirin in cardiology, pharmacology, and neurology. \u0000 \u0000A general review on aspirin pharmacology was made by Espinosa et al. (Western University of Health Sciences, Pomona, CA, USA). This review article helps to understand the role of platelets in primary hemostasis and atherothrombosis, the use of aspirin in the prevention, and treatment of cardiovascular diseases. \u0000 \u0000In the review article by B. Rocca and G. Petrucci (Catholic University School of Medicine, Rome, Italy), they have detailed the phenomenon of variability in the responsiveness to low-dose aspirin and reported the explanations of this real problem in patients. \u0000 \u0000The clinical use of aspirin in treatment and prevention of cardiovascular diseases was the subject of the work of Y. Dai and J. Ge (Fudan University, Shanghai, China). In this paper, the authors review the different clinical situations when aspirin is administered. \u0000 \u0000The use of aspirin for prevention of thrombosis was clearly discussed by G. H. R. Rao and J. Fareed (University of Minnesota, Minneapolis, MN and Loyola University Medical Center, Maywood, IL, USA). \u0000 \u0000The special work on the role of dermcidin isoform 2 by Ghosh et al. (Calcutta, India) completes the two clinical papers. \u0000 \u0000The work of Losche et al. (Jena University Hospital, Jena, Germany) on the problem of the reduction of mortality in critically ill patients also demonstrates the effectiveness of antiplatelet drugs to prevent organ failure. \u0000 \u0000The three experimental studies from the laboratory of Doutremepuich concern the paradoxical action of aspirin used at different dosages. These different effects can explain the thrombosis observed in clinical practice after aspirin discontinuation. The question could be also: what is the effect of a drug at ultralow dose? \u0000 \u0000In conclusion, this special issue can represent a “state of art” on aspirin and thrombosis with new hypotheses of work.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"626289"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/626289","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31046697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}